Toronto-based Psyence Biomedical Ltd (NASDAQ: PBM) just invested US$500,000 into the private South African drug developer PsyLabs. The capital injection follows Psyence taking an 11 per cent stake in the natural psychedelics company in September.
PsyLabs is federally licensed to produce psilocybin, psilocin, mescaline, DMT and ibogaine for international research partners at its facility in Cape Town. It has been in operation for four years. The extraction ...